Ventyx Biosciences
VTYX | NASDAQ
$14.00
$0.00 (0.00%)
At close: Mar 3, 2026, 4:00 PM ET
Ventyx Biosciences Company Profile
Company profile explainedCompany Profile
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1) modulator, which has advanced to Phase II clinical studies for the treatment of ulcerative colitis. Additionally, VTX2735, a peripherally targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor, is in Phase I development, intended to combat systemic inflammatory diseases affecting cardiovascular, hepatic, renal, and rheumatologic systems. Furthermore, Ventyx is engaged in the development of CNS-penetrant NLRP3 inhibitors, with the objective of providing therapies for neurological ailments such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Founded in 2018, Ventyx Biosciences, Inc. is headquartered in Encinitas, California.
Key Executives
| Name | Position |
|---|---|
| Raju S. Mohan | Founder, Chief Executive Officer, President & Director |
| Matthew Richard Moore | Chief Operating Officer |
| Arline Nakanishi | Senior Vice President of Biometrics |
| John Nuss | Chief Scientific Officer |
| Kathy Ogilvie | Senior Vice President of Translational & Nonclinical Research |
| Mark S. Forman | Chief Medical Officer |
| Roy Gonzales | Senior Vice President of Finance and Principal Financial & Accounting Officer |
| Sheila K. Gujrathi | Executive Chairperson |
| Snehal Naik | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| May 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| May 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Mar 16, 2026 | 15-12G | Filing |
| Mar 06, 2026 | EFFECT | Filing |
| Mar 06, 2026 | EFFECT | Filing |
| Mar 05, 2026 | SC 13D/A | [Amend] Filing |
| Mar 04, 2026 | 4 | Filing |
| Mar 04, 2026 | 4 | Filing |
| Mar 04, 2026 | 4 | Filing |
Ventyx Biosciences
| Country | United States |
| IPO Date | Oct 21, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 81 |
| CEO | Sheila K. Gujrathi |
Contact Details
662 Encinitas Boulevard San Diego,
California 92024 United States
Stock Details
| Ticker Symbol | VTYX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001851194 |
| CUSIP Number | 92332V107 |
| ISIN Number | US92332V1070 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove VTYX